Ketamine is under clinical development by AWAKN Life Sciences and currently in Phase I for Binge Eating Disorder. According to GlobalData, Phase I drugs for Binge Eating Disorder have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine overview
Ketamine is under development for the treatment of alcohol use disorder (AUD) and gambling addiction to include three other behavioral addictions including binge eating disorder, compulsive sexual behaviour, internet gaming disorder. The drug candidate is administered through intravenous route. It acts by targeting N-methyl-D-aspartate (NMDA) receptor.
AWAKN Life Sciences overview
AWAKN Life Sciences (AWAKN) is a provider of evidence-based psychedelic assisted psychotherapy solutions to heal mental health conditions. AWAKN is headquartered in Toronto, Ontario, Canada.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
